The FDA has approved a new freeze-dried formulation of Jynneos (smallpox and mpox vaccine, live, non-replicating).

Denmark's Bavarian Nordic said on Monday the U.S. Food and Drug Administration has approved a freeze-dried formulation of its mpox and smallpox vaccine.

The freeze-dried formulation provides flexibility with regard to storage and shelf life. The Food and Drug Administration (FDA) has approved a new freeze-dried formulation of Jynneos ® (smallpox ...

The formulation allows for greater stockpiling, with Bavarian Nordic already working with the US government to add to vaccine reserves.

The US Food and Drug Administration (FDA) has approved the freeze-dried formulation of Bavarian Nordic’s smallpox and mpox vaccine in a move expected to provide flexibility in stockpiling the jab.

Approved by the FDA in 2019, JYNNEOS was the first smallpox vaccine successfully developed under Project BioShield, a program created by the U.S. Congress in 2004 to accelerate the research ...

March 31 (Reuters) - Denmark's Bavarian Nordic (BAVA.CO), opens new tab said on Monday the U.S. Food and Drug Administration has approved a freeze-dried formulation of its mpox and smallpox vaccine.

COPENHAGEN, Denmark, March 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the U.S. Food and Drug Administration (FDA) has approved the freeze-dried formulation of JYNNEOS ...

Approved by the FDA in 2019, JYNNEOS was the first smallpox vaccine successfully developed under Project BioShield, a program created by the U.S. Congress in 2004 to accelerate the research ...